Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies
Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.
How this was made

The 30-second read
Why it matters
The acquisition adds Contego’s recently FDA-approved Neuroguard IEP Direct System, described as the first and only TCAR-IEP system with integrated embolic protection plus flow reversal, expanding Medtronic’s differentiated carotid technology portfolio.
Market read
Traders can reassess MDT’s deal-driven valuation and near-term EPS risk given the stated $380M price, expected Q3 FY closing, and EPS dilution/accretion profile.
What to watch
Closing conditions, regulatory/competitive review timing, and whether Neuroguard IEP adoption ramps faster or slower than expected could dominate the stock reaction more than the headline valuation.
Background
Contego Medical is a privately held device maker focused on carotid artery disease and peripheral thrombectomy, with an exclusive US distribution agreement with Medtronic announced in January 2025.
Ticker impact
Medtronic announces intent to acquire Contego Medical for $380M, adding the FDA-approved Neuroguard IEP Direct System to its carotid portfolio.
Likely modest upside bias as investors price in portfolio expansion and potential EPS neutrality after FY28, tempered by deal-risk and integration uncertainty.
The article provides deal value ($380M), timing (Q3 FY), and EPS dilution/accretion expectations, which are direct inputs for valuation and risk assessment.
Market effects
Could strengthen competitive positioning in carotid revascularization and embolic protection devices, potentially increasing M&A and product-cycle focus in vascular intervention.
US-focused distribution and FDA-approved system may shift near-term demand expectations for TCAR-IEP adoption in the US.
If the technology scales beyond the US, it may influence global vascular intervention competitive dynamics and procurement preferences.
Counterpoint
Investors may discount the strategic value if the acquisition is only minimally dilutive near-term and accretive later, implying limited immediate earnings lift.
Key entities
- companyMedtronic
US-listed healthcare technology company announcing intent to acquire Contego Medical for $380M.
- companyContego Medical
Privately held medical device company developing integrated embolic protection for TCAR-IEP, including Neuroguard IEP Direct System.
- productNeuroguard IEP Direct System
Recently FDA-approved transcarotid artery revascularisation system with integrated embolic protection and flow reversal.

